## Antiarrhythmic Drug Selection in Post-MI Ventricular Arrhythmias ### Clinical Context Post-MI patients with ventricular arrhythmias require careful drug selection because many antiarrhythmics carry proarrhythmic risk, particularly in the setting of structural heart disease. ### Analysis of Each Option | Drug | Class | Key Properties | Safety Profile | |------|-------|-----------------|----------------| | Amiodarone | I, II, III, IV | Pan-antiarrhythmic; effective SVT & VT | Safe in structural disease; organ toxicity | | Flecainide | Ic | Fast Na⁺ blocker; minimal repolarization effect | **Contraindicated in structural disease** | | Sotalol | III + II | K⁺ blocker + β-blocker | **Risk of torsades; not universally safe** | | Procainamide | Ia | Na⁺ blocker + K⁺ blocker | Lupus-like syndrome with chronic use | **Option 1 (Amiodarone) — CORRECT** - Class I: sodium channel blockade - Class II: beta-blocking effects - Class III: potassium channel blockade (dominant effect) - Class IV: calcium channel blockade - Effective for both atrial fibrillation and ventricular arrhythmias - Paradoxically safe in structural heart disease despite its potency **Option 2 (Flecainide) — CORRECT** - Class Ic agent (minimal effect on repolarization) - **CAST trial (1989)**: Flecainide increased mortality in post-MI patients with ventricular ectopy - Contraindicated in structural heart disease, prior MI, and reduced ejection fraction - Safe only in structurally normal hearts (e.g., paroxysmal SVT) **Option 3 (Sotalol) — INCORRECT** - Combines Class III (potassium channel blockade) with Class II (beta-blockade) - **NOT universally safe** in all patients with ventricular arrhythmias - Risk of **torsades de pointes** (polymorphic VT), especially in: - Hypokalemia - Hypomagnesemia - Bradycardia - Female gender - Renal impairment - Requires careful monitoring of QT interval and electrolytes - Contraindicated in baseline QT prolongation **Option 4 (Procainamide) — CORRECT** - Class Ia antiarrhythmic (sodium and potassium channel blockade) - Well-known adverse effect: **lupus-like syndrome** (positive ANA, arthralgia, fever) - Occurs in 20–30% of patients on chronic therapy - More common in slow acetylators - Reversible upon drug discontinuation **Key Point:** Sotalol is NOT safe for use in "all patients" with ventricular arrhythmias. It carries significant proarrhythmic risk (torsades de pointes) and requires careful patient selection, electrolyte monitoring, and QT interval surveillance. **High-Yield:** The CAST trial fundamentally changed antiarrhythmic practice: Class Ic drugs (flecainide, encainide) increase mortality in post-MI patients despite suppressing ectopy. This led to the principle that **"suppression of arrhythmias does not equal improved survival."** **Clinical Pearl:** In post-MI ventricular arrhythmias: - **First-line:** Beta-blockers and ACE inhibitors (reduce mortality) - **Second-line:** Amiodarone (if EF <40% and symptomatic VT) - **Avoid:** Class Ic drugs, sotalol (without careful selection) - **Device therapy:** ICD for secondary prevention **Mnemonic: "CAST LESSON"** - **C** — Class Ic drugs (flecainide, encainide) - **A** — Arrhythmia suppression ≠ survival benefit - **S** — Structural heart disease = contraindication - **T** — Trial proved mortality increase - **L** — Lesson: use amiodarone or devices instead - **E** — Ejection fraction matters - **S** — Sotalol also risky (torsades) - **S** — Slow acetylators get lupus from procainamide - **O** — Only amiodarone is truly safe in structural disease - **N** — Never use flecainide post-MI
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.